6 days CHMP Endorses J&J’s Rybrevant-Lazcluze Combo for Use in NSCLCZacks

The CHMP’s opinion is based on late-stage study data, which show that treatment with JNJ’s combo drug reduces the risk of disease progression or death by 30% in certain NSCLC patients.

Johnson & Johnson (JNJ)